Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2:: a clinical report
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2:: a clinical report
复制标题
DOI：
10.1016/s0959-8049(02)00479-3
复制
发表时间：
2003-01-01
影响因子：
8.4
通讯作者：
Stoter, G
中科院分区：
文献类型：
--
作者：
Marchand, M;Punt, CJA;Stoter, G
57名患有法师-3阳性可测量的转移性癌症的患者，其中大多数患有黑色素瘤，用递增剂量的重组法师-3蛋白与固定剂量的免疫佐剂SBAS-2（其含有MPL和QS 21）组合进行疫苗接种。免疫时间表包括4次肌内（i.m.）每隔3周注射一次。在4次疫苗接种后肿瘤稳定或消退的患者接受2次额外的疫苗接种，间隔6周。疫苗一般耐受性良好。在33例可评价肿瘤缓解的黑色素瘤患者中，我们观察到2例部分缓解、2例混合缓解和1例稳定。这5例患者的至进展时间为4至29个月。此外，在纳入的3例转移性膀胱癌患者中的1例中观察到持续10个月的部分缓解。上述肿瘤缓解均不涉及内脏转移。对疫苗的免疫反应将单独报告。(C)2002爱思唯尔科技有限公司版权所有。
Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately. (C) 2002 Elsevier Science Ltd. All rights reserved.